PREMIER--LIFESTYLE INTERVEN FOR BLOOD PRESSURE CONTROL

总理——通过生活方式干预控制血压

• 批准号: 6056620
• 负责人: PATRICIA J. ELMER
• 金额: $ 72.68万
• 依托单位: KAISER FOUNDATION RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-25 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6056620
• 关键词: alcoholic beverage consumption; behavioral /social science research tag; blood chemistry; cardiovascular disorder prevention; clinical research; cooperative study; diet therapy; dietary lipid; exercise; fruit; health behavior; human subject; human therapy evaluation; hypertension; lifestyle; low salt diet; nutrition related tag; vegetables; weight loss

This application is part of a set of applications from five participating institutions. PREMIER, a randomized clinical trial, will determine how two multi-component lifestyle interventions affect blood pressure (BP). Although numerous organizations recommend lifestyle change to control BP and potentially prevent hypertension, practical implementation strategies have yet to be developed and tested. The two lifestyle interventions to be tested in PREMIER include a "comprehensive" intervention implementing current recommendations for BP control (reduced salt intake; increased physical activity, moderation of alcohol intake; and weight loss, if appropriate), and a "comprehensive plus DASH" intervention implementing current recommendations plus the Dietary Approaches to Stop Hypertension (DASH) dietary pattern (rich in fruits, vegetables, and low-fat dairy products, and reduced in saturated fat, total fat, and cholesterol). These lifestyle intervention programs will consist of a series of group and individual counseling sessions similar in intensity to health education programs currently provided by health care delivery systems for other conditions. Study participants (n=800) will be 25 years of age or older, with systolic BP of 120-159 mmHg and diastolic BP of 80-95 mmHg. Approximately half of the participants will be female, 40 percent will be African American, and 30 percent will have stage 1 hypertension. After three screening visits, participants Will be randomly assigned to one of the two lifestyle interventions or a usual care control group. Follow-up will last 18 months after randomization. The primary outcome will be systolic BP with diastolic BP as a secondary outcome. Additional outcome variables will include fasting lipids, fasting glucose, insulin, and homocysteine. The trial hypotheses will be examined in all participants as well as separately in non-hypertensive and hypertensive subgroups. Results from PREMIER will provide the scientific rationale for routinely implementing comprehensive lifestyle intervention programs to control BP and ultimately prevent BP-related cardiovascular disease.

该应用程序是来自五个应用程序的一组应用程序的一部分 参与机构。 PREMIER 是一项随机临床试验，将 确定两种多成分生活方式干预措施如何影响血液 压力（BP）。 尽管许多组织推荐生活方式 改变以控制血压并可能预防高血压，实用 实施战略仍有待制定和测试。两人 PREMIER 中待测试的生活方式干预措施包括 实施当前建议的“全面”干预 血压控制（减少盐摄入量；增加体力活动，适度 酒精摄入量；和减肥（如果适用），以及 “综合+DASH”干预实施当前 建议以及控制高血压的饮食方法 (DASH) 饮食模式（富含水果、蔬菜和低脂乳制品， 并减少饱和脂肪、总脂肪和胆固醇）。 这些 生活方式干预计划将包括一系列小组和 个人咨询课程的强度与健康教育相似 目前由医疗保健提供系统为其他国家提供的计划 状况。 研究参与者 (n=800) 年龄为 25 岁或 年龄较大，收缩压为120-159毫米汞柱，舒张压为80-95毫米汞柱。 大约一半的参与者是女性，40% 非洲裔美国人中，30% 的人患有 1 期高血压。 经过三次筛选访问后，参与者将被随机分配到 两种生活方式干预措施之一或常规护理对照组。 随机分组后随访将持续 18 个月。 主要结果 将收缩压和舒张压作为次要结果。 其他结果变量包括空腹血脂、空腹 葡萄糖、胰岛素和同型半胱氨酸。 试验假设将是 对所有参与者以及非高血压参与者进行单独检查 和高血压亚组。 PREMIER 的结果将提供 常规实施综合生活方式的科学道理 控制血压并最终预防血压相关的干预计划 心血管疾病。